It enrolled 938 adults with a body mass index of 27 or more and an HbA1c of 7% to 10%, and gave them tirzepatide 10 mg or 15 mg, or placebo, once a week for 72 weeks. Weight fell by 12.8% and 14.7% on the two doses, against 3.2% on placebo. It was published in The Lancet in 2023.1
How the trial was run
The trial was double-blind and ran in seven countries. Participants, investigators and the sponsor did not know who received which treatment. Between March 2021 and April 2023, 938 of 1,514 adults assessed were assigned in equal shares: 312 to 10 mg, 311 to 15 mg and 315 to placebo.1
At the start, participants averaged 54.2 years of age, 100.7 kg and a body mass index of 36.1, with an average HbA1c of 8.02%. Half were women, 76% were White and 60% Hispanic or Latino.1 The two main outcomes were the percentage change in weight and the share losing at least 5%.
What it found
- Weight fell by 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo: differences of 9.6 and 11.6 percentage points.
- A loss of at least 5% was reached by 79% to 83% on tirzepatide, against 32% on placebo.
- The most frequent side effects were in the stomach and gut, including nausea, diarrhea and vomiting, mostly mild to moderate; fewer than 5% stopped because of them.
Garvey et al., 2023.1
Serious adverse events were reported by 68 participants across the three groups, 7% of all who took part. Two deaths occurred in the 10 mg group; the investigators did not consider them related to the study treatment. The authors concluded that tirzepatide 10 mg and 15 mg gave a substantial and clinically meaningful reduction in body weight in adults with obesity and type 2 diabetes.1
The Zepbound label includes this trial as its Study 2 and reports the same weight changes.2 Zepbound itself is approved for weight, while the same molecule is sold as Mounjaro for blood sugar control in type 2 diabetes.2,3
Why the loss is smaller with diabetes
The same doses lowered weight more in SURMOUNT-1, in adults without diabetes: 19.5% on 10 mg and 20.9% on 15 mg, against 12.8% and 14.7% here.4 Semaglutide shows the same pattern: 14.9% without diabetes in STEP 1 and 9.6% with it in STEP 2.5,6 The trials do not explain the gap, but it is consistent across the class, and it matters for expectations. A person with type 2 diabetes who compares their progress with headline numbers from trials in people without diabetes will usually fall short of them.
Low blood sugar
People with diabetes often take other medicines that lower blood sugar. The Zepbound label reports that in this trial, readings below 54 mg/dL occurred in 4.2% on tirzepatide against 1.3% on placebo, and it warns that combining tirzepatide with insulin or a sulfonylurea raises the risk.2 Doses of those medicines may need to be lowered when tirzepatide starts, a decision for the prescriber.
Limits
SURMOUNT-2 enrolled people with an HbA1c of 7% to 10%, so it says little about people with very high blood sugar. It did not include the 5 mg dose, so it cannot say how the lowest maintenance dose works in people with diabetes. It was funded by Eli Lilly and Company, the maker of tirzepatide.1 Our page on Mounjaro and Zepbound explains which brand covers which use.
Sources
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613-626. Funded by Eli Lilly and Company. doi:10.1016/S0140-6736(23)01200-X
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 5, 6.1 and 14. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
- Davies M, F忙rch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971-984. doi:10.1016/S0140-6736(21)00213-0
Related analyses
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Ozempic vs Mounjaro: what the head-to-head trial and the two labels show
Zepbound dosing schedule: every step from 2.5 to 15 mg, with your dates
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Log your weight and HbA1c and see both trends on one screen.
Open Dose Insider